Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Stedman

Forensic Psychiatry Tampa, FL Medical Doctor

NPI 1457304644 CMS profile 19962

14506 University Point Pl, Tampa, FL 33613

Open in the dashboard

General payments

$19,101

315 records reported · program years 2019–2025

Research payments

$72,044

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,590,063 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mary Stedman of Tampa, FL is reported in the CMS Open Payments database as having received $19,101 across 315 general payments and $72,044 in research payments paid to them. Separately, studies naming them as principal investigator received $4,590,063 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Forensic Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,642 80
2024 General $8,086 40
2024 Research $9,812 1
2023 General $1,678 53
2023 Research $2,924 5
2022 General $1,560 59
2022 Research $5,950 3
2021 General $1,355 39
2021 Research $40,049 2
2020 General $309 14
2019 General $1,472 30
2019 Research $13,309 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Stedman
  • Forensic Psychiatry median
  • Middle half of Forensic Psychiatry
  • National median

In program year 2025, general payments to Mary Stedman were reported at $4,642. Among 86 Forensic Psychiatry profiles paid that year, the median was $125 and the middle half received between $34 and $306.

Show as a table
Year Mary Stedman Forensic Psychiatry median Middle half National median
2019 $1,472 $143 $61–$431 $163
2020 $309 $112 $36–$301 $114
2021 $1,355 $113 $38–$343 $132
2022 $1,560 $113 $67–$475 $149
2023 $1,678 $139 $66–$415 $160
2024 $8,086 $117 $36–$341 $164
2025 $4,642 $125 $34–$306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $7,310 21 payments
  2. Neurocrine Biosciences, Inc. $2,818 20 payments
  3. Neuronetics, Inc. $1,494 27 payments
  4. Eisai Inc. $1,149 28 payments
  5. AbbVie, Inc. $1,032 42 payments
  6. Otsuka America Pharmaceutical, Inc. $920 34 payments
  7. Alkermes, Inc. $904 34 payments
  8. ITI, Inc. $798 26 payments
  9. Axsome Therapeutics, Inc. $595 12 payments
  10. Janssen Pharmaceuticals, Inc $590 23 payments
  11. Other $1,490 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,350 300 payments
  2. Honoraria $5,200 1 payment
  3. Travel and Lodging $3,464 11 payments
  4. Education $86 3 payments
Products named General payments · program years 2019–2025
  1. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR $6,848 6 payments
  2. VRAYLAR $953 38 payments
  3. REXULTI $920 34 payments
  4. LYBALVI $812 33 payments
  5. ARISTADA Cns $604 28 payments
  6. ARISTADA Cns $604 28 payments
  7. Auvelity $595 12 payments
  8. SPRAVATO $590 23 payments
  9. Leqembi $565 16 payments
  10. NEUROSTAR TMS THERAPY $537 12 payments
  11. Other $5,882 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $58,735 11 payments
  2. ACADIA Pharmaceuticals Inc $10,573 5 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,737 14 payments

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

506

Median for Psychiatry: 574

Drug cost

$97,361

Median for Psychiatry: $27,624

Branded share of claims

24.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 21 $43,107
Auvelity Dextromethorphan Hbr/Bupropion Brand 24 $25,692
Rexulti Brexpiprazole Brand 12 $19,404
Vilazodone Hcl Generic 25 $3,076
Lamotrigine Generic 49 $739
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 20 $651
Buspirone Hcl Generic 32 $641
Venlafaxine Hcl Er Venlafaxine Hcl Brand 12 $613
Bupropion Xl Bupropion Hcl Brand 24 $603
Quetiapine Fumarate Generic 26 $580

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$29,980

Medicare's payments for the services billed

Medicare patients

35

Average age 71

Services billed

412

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 69%
Arthritis 63%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $241
  • Lundbeck LLC $33
$274 12 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $189
$189 21 —
VRAYLAR
  • AbbVie, Inc. $155
$155 — —
LYBALVI
  • Alkermes, Inc. $138
$138 — —
Auvelity
  • Axsome Therapeutics, Inc. $126
$126 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

345 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Forensic Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record